Advances in Studies of Chiglitazar Sodium, a Novel PPAR Pan-Agonist, for the Treatment of Type 2 Diabetes Mellitus

Abstract

Chiglitazar sodium is a new peroxisome proliferator-activated receptor (PPAR) pan-agonist with independent intellectual property rights in China. It can treat type 2 diabetes mellitus and regulate metabolism by modestly activating PPARα, PPARγ, and PPARδ to improve insulin sensitivity, regulate blood glucose, and promote fatty acid oxidation and utilization. Chiglitazar sodium has a significant insulin-sensitizing effect and is advantageous in reducing fasting and postprandial blood glucose levels, particularly at the 48 mg dose in patients with concomitant high triglycerides in terms of blood glucose and triglyceride level control.

Keywords

chiglitazar sodium / type 2 diabetes mellitus / peroxisome proliferator-activated receptor / effectiveness / safety

References

[1] AthyrosVG, DoumasM, ImprialosKP, et al.. Diabetes and lipid metabolism. Hormones (Athens), 2018, 17(1): 61-67

[2] JaveedN, MatveyenkoAV. Circadian Etiology of Type 2 Diabetes Mellitus. Physiology (Bethesda), 2018, 33(2): 138-150

[3] Mayer-DavisEJ, LawrenceJM, DabeleaD, et al.. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012. N Engl J Med, 2017, 376(15): 1419-1429

[4] KahnSE, HaffnerSM, HeiseMA, et al.. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med, 2006, 355(23): 2427-2443

[5] SoccioRE, ChenER, LazarMA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab, 2014, 20(4): 573-591

[6] LiPP, ShanS, ChenYT, et al.. The PPAR alpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. Brit J Pharmacol, 2006, 148(5): 610-618

[7] PanDS, WangW, LiuNS, et al.. Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPARγ. PPAR Res, 2017, 2017: 4313561

[8] HeBK, NingZQ, LiZB, et al.. In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist. PPAR Res, 2012, 2012: 546548

[9] GrossB, PawlakM, LefebvreP, et al.. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Rev Endocrinol, 2016, 13(1): 36-49

[10] DeeksED. Chiglitazar: First Approval. Drugs, 2022, 82(1): 87-92

[11] HaluzíkMM, HaluzíkM. PPAR-alpha and insulin sensitivity. Physiol Res, 2006, 55(2): 115-122

[12] CabreroA, AlegretM, SánchezRM, et al.. Bezafibrate reduces mRNA levels of adipocyte markers and increases fatty acid oxidation in primary culture of adipocytes. Diabetes, 2001, 50(8): 1883-1890

[13] ChenT, ZhangY, LiuY, et al.. MiR-27a promotes insulin resistance and mediates glucose metabolism by targeting PPAR-γ-mediated PI3K/AKT signaling. Aging (Albany NY), 2019, 11(18): 7510-7524

[14] KameneckaTM, BusbySA, KumarN, et al.Potent Anti-Diabetic Actions of a Novel Non-Agonist PPARγ Ligand that Blocks Cdk5-Mediated Phosphorylation, 2011, Bethesda (MD), National Center for Biotechnology Information (US)

[15] YessoufouA, WahliW. Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels. Swiss Med Wkly, 2010, 140: w13071

[16] HanL, ShenWJ, BittnerS, et al.. PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part III: PPAR-β/δ and PPAR-γ. Future Cardiol, 2017, 13(3): 279-296

[17] MontaigneD, ButruilleL, StaelsB. PPAR control of metabolism and cardiovascular functions. Nat Rev Cardiol, 2021, 18(12): 809-823

[18] SullivanHJ, WangX, NogleS, et al.. To Probe Full and Partial Activation of Human Peroxisome Proliferator-Activated Receptors by Pan-Agonist Chiglitazar Using Molecular Dynamics Simulations. PPAR Res, 2020, 2020: 5314187

[19] YanLP, DouGF. In vitro metabolism of chiglitazar. J Chin J Pharmacol Toxicol (Chinese), 2007, 21(2): 124-130

[20] ChoiJH, BanksAS, KameneckaTM, et al.. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature, 2011, 477(7365): 477-481

[21] XuHR, ZhangJW, ChenWL, et al.. Pharmacokinetics, Safety and Tolerability of Chiglitazar, A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, in Healthy Chinese Volunteers: A Phase I Study. Clin Drug Invest, 2019, 39(6): 553-563

[22] LiX, YuJ, WuM, et al.. Pharmacokinetics and Safety of Chiglitazar, a Peroxisome Proliferator-Activated Receptor Pan-Agonist, in Patients < 65 and ≥ 65 Years With Type 2 Diabetes. Clin Pharmacol Drug Dev, 2020, 10(7): 789-796

[23] YiL, ZhangH, ZhangJW, et al.. Study on Drug-Drug Interactions Between Chiglitazar, a Novel PPAR Pan-Agonist and Metformin Hydrochloride in Healthy Subjects. Clin Pharmacol Drug Dev, 2019, 8(7): 934-941

[24] LyuX, GaoY, ZhuL, et al.. Efcacy and safety of chiglitazar in type 2 diabetes: a multi-center, randomized, double-blind andparallel group clinical trial. J China Diabetes Mellitus (Chinese), 2019, 11(5): 334-340

[25] JiL, SongW, FangH, et al.. Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP). Sci Bull (Beijing), 2021, 66(15): 1571-1580

[26] JiaW, MaJ, MiaoH, et al.. Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS). Sci Bull (Beijing), 2021, 66(15): 1581-1590

[27] ZhouY, WangH, WangY, et al.. Comparative Evaluation of Chiglitazar and Sitagliptin on the Levels of Retinol-Binding Protein 4 and Its Correlation With Insulin Resistance in Patients With Type 2 Diabetes. Front Endocrinol (Lausanne), 2022, 13: 801271

[28] WangY, LiH, GaoH, et al.. Effect of chiglitazar and sitagliptin on glucose variations, insulin resistance and inflammatory-related biomarkers in untreated patients with type 2 diabetes. Diabetes Res Clin Pract, 2021, 183: 109171